The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells

Journal of Clinical Investigation

Volumn 113, Issue 11, 2004, Pages 1631-1640

  Oki, Shinji ^a   Chiba, Asako ^a   Yamamura, Takashi ^a   Miyake, Sachiko ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; GLYCOLIPID; INTERLEUKIN 4; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR REL;

ANIMAL CELL; ARTICLE; CYTOKINE PRODUCTION; IMMUNOMODULATION; INTERFERON PRODUCTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; ANIMAL; BIOSYNTHESIS; KINETICS; METABOLISM; T LYMPHOCYTE;

ANIMALS; GLYCOLIPIDS; INTERFERON TYPE II; INTERLEUKIN-4; KILLER CELLS, NATURAL; KINETICS; MICE; PROTO-ONCOGENE PROTEINS C-REL; T-LYMPHOCYTES;

EID: 2942739333     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200420862     Document Type: Article

References (45)

1. Kronenberg, M., and Gapin, L. 2002. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2:557-568.
2. Taniguchi, M., Harada, M., Kojo, S., Nakayama, T., and Wakao, H. 2003. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21:483-513.
3. Brossay, L., et al. 1998. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 188:1521-1528.
4. Kawano, T., et al. 1997. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides. Science. 278:1626-1629.
5. Spada, P.M., et al. 1998. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J. Exp. Med. 188:1529-1534.
6. Carnaud, C., et al. 1999. Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163:4647-4650.
7. Fujii, S.I., Shimizu, K., Smith, C., Bonifaz, L., and Steinman, R.M. 2003. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198:267-279.
8. Chiba, A., et al. 2004. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of α-galactosylceramide. Arthritis Rheum. 50:305-313.
9. Miyamoto, K., Miyake, S., and Yamamura, T. 2001. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature. 413:531-534.
10. Burdin, N., et al. 1998. Selective ability of mouse CD1 to present glycolipids: α-galactosylceramide specifically stimulates Vα 14+ NKT lymphocytes. J. Immunol. 161:3271-3281.
11. De Silva, A.D., et al. 2002. Lipid protein interactions: the assembly of CD1d1 with cellular phospholipids occurs in the endoplasmic reticulum. J. Immunol. 168:723-733.
12. Antonsson, A., Hughes, K., Edin, S., and Grundstrom, T. 2003. Regulation of c-Rel nuclear localization by binding of Ca2+/calmodulin. Mol. Cell. Biol. 23:1418-1427.
13. Moody, D.B., et al. 2002. Lipid length controls antigen entry into endosomal and nonendosomal pathways for CD1b presentation. Nat. Immunol. 3:435-442.
14. Fujii, S., Shimizu, K., Kronenberg, M., and Steinman, R.M. 2002. Prolonged IFN-γ-producing NKT response induced with α- galactosylceramide-loaded DCs. Nat. Immunol. 3:867-874.
15. Akbari, O., et al. 2003. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat. Med. 31:31.
16. Heller, F., Fuss, I.J., Nieuwenhuis, E.E., Blumberg, R.S., and Strober, W. 2002. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity. 17:629-638.
17. Leite-de-Moraes, M.C., et al. 2002. Ligand-activated natural killer T lymphocytes promptly produce IL-3 and GM-CSF in vivo: relevance to peripheral myeloid recruitment. Eur. J. Immunol. 32:1897-1904.
18. Chen, H., Huang, H., and Paul, W.E. 1997. NK1.1+ CD4+ T cells lose NK1.1 expression upon in vitro activation. J. Immunol. 158:5112-5119.
19. Venkataraman, L., Burakoff, S.J., and Sen, R. 1995. FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells. J. Exp. Med. 181:1091-1099.
20. Milliard, B.A., et al. 2002. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J. Clin. Invest. 110:843-850. doi:10.1172/JCI200215254.
21. Carrasco, D., et al. 1998. Multiple hemopoietic defects and lymphoid hyperplasia in mice lacking the transcriptional activation domain of the c-Rel protein. J. Exp. Med. 187:973-984.
22. Matsuda, J.L., et al. 2003. Mouse Vα14i natural killer T cells are resistant to cytokine polarization in vivo. Proc. Natl. Acad. Sci. U. S. A. 100:8395-8400.
23. Tsytsykova, A.V., Tsitsikov, E.N., and Geha, R.S. 1996. The CD40L promoter contains nuclear factor of activated T cells-binding motifs which require AP-1 binding for activation of transcription. J. Biol. Chem. 271:3763-3770.
24. Parra, E., Mustelin, T., Dohlsten, M., and Mercola, D. 2001. Identification of a CD28 response element in the CD40 ligand promoter. J. Immunol. 166:2437-2443.
25. Kitamura, H., et al. 1999. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189:1121-1128.
26. + T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood. 99:1259-1266.
27. Schmieg, J., Yang, G., Franck, R.W., and Tsuji, M. 2003. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J. Exp. Med. 198:1631-1641.
28. Brigl, M., Bry, L., Kent, S.C., Gumperz, J.E., and Brenner, M.B. 2003. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4:1230-1237.
29. Zeng, Z., et al. 1997. Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove. Science. 277:339-345.
30. Cantu, C., 3rd, Benlagha, K., Savage, P.B., Bendelac, A., and Teyton, L. 2003. The paradox of immune molecular recognition of α-galactosylceramide: low affinity, low specificity for CD1d, high affinity for αβ TCRs. J. Immunol. 170:4673-4682.
31. Benlagha, K., Weiss, A., Beavis, A., Teyton, L., and Bendelac, A. 2000. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J. Exp. Med. 191:1895-1903.
32. Evavold, B.D., and Allen, P.M. 1991. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science. 252:1308-1310.
33. Chaturvedi, P., Yu, Q., Southwood, S., Sette, A., and Singh, B. 1996. Peptide analogs with different affinities for MHC alter the cytokine profile of T helper cells. Int. Immunol. 8:745-755.
34. Boutin, Y., Leitenberg, D., Tao, X., and Bottomly, K. 1997. Distinct biochemical signals characterize agonist- and altered peptide ligand-induced differentiation of naive CD4+ T cells into Th1 and Th2 subsets. J. Immunol. 159:5802-5809.
35. Zhu, J., and McKeon, F. 2000. Nucleocytoplasmic shuttling and the control of NF-AT signaling. Cell. Mol. Life Sci. 57:411-420.
36. Venkataraman, L., Wang, W., and Sen, R. 1996. Differential regulation of c-Rel translocation in activated B and T cells. J. Immunol. 157:1149-1155.
37. Ghosh, P., Tan, T.H., Rice, N.R., Sica, A., and Young, H.A. 1993. The interleukin 2 CD28-responsive complex contains at least three members of the NF κ B family: c-Rel, p50, and p65. Proc. Natl. Acad. Sci. U. S. A. 90:1696-1700.
38. Rao, S., Gerondakis, S., Woltring, D., and Shannon, M.F. 2003. c-Rel Is required for chromatin remodeling across the IL-2 gene promoter. J. Immunol. 170:3724-3731.
39. Gerondakis, S., et al. 1996. Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor. Proc. Natl. Acad. Sci. U. S. A. 93:3405-3409.
40. Kontgen, F., et al. 1995. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 9:1965-1977.
41. Wang, W., Tam, W.F., Hughes, C.C., Rath, S., and Sen, R. 1997. c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. Immunity. 6:165-174.
42. Rott, O., Cash, E., and Fleischer, B. 1993. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur. J. Immunol. 23:1745-1751.
43. Aronica, M.A., et al. 1999. Preferential role for NF-κ B/Rel signaling in the type 1 but not type 2 T cell-dependent immune response in vivo. J. Immunol. 163:5116-5124.
44. Feske, S., Draeger, R., Peter, H.H., Eichmann, K., and Rao, A. 2000. The duration of nuclear residence of NFAT determines the pattern of cytokine expression in human SCID T cells. J. Immunol. 165:297-305.
45. Portet, C.M., and Clipstone, N.A. 2002. Sustained NFAT signaling promotes a Th1-like pattern of gene expression in primary murine CD4+ T cells. J. Immunol. 168:4936-4945.